Vericel (VCEL) Shares Outstanding (Diluted Average) (2010 - 2026)
Vericel's (VCEL) quarterly Shares Outstanding (Diluted Average) came in at $50.8 million in Q1 2026, up 1.74% year-on-year from $49.9 million in Q1 2025, and down 2.64% quarter-over-quarter from $52.2 million in Q4 2025.
Vericel (VCEL) Shares Outstanding (Diluted Average) (2010 - 2026) Analysis & Trends
Vericel has disclosed Shares Outstanding (Diluted Average) across 12 years of filings, most recently posting $50.8 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $50.8 million, up 1.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.8 million (up 1.74% YoY), and the FY2025 annual result was $52.2 million, up 0.91% from the prior year.
- Shares Outstanding (Diluted Average) came in at $50.8 million for Q1 2026 at Vericel, down from $52.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $52.2 million in Q4 2025 to a low of $47.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $48.1 million (2024), against an average of $48.8 million.
- Across the five-year window, Shares Outstanding (Diluted Average) advanced 0.86% in 2023 and climbed 8.59% in 2024, its largest moves.
- Vericel's Shares Outstanding (Diluted Average) stood at $47.1 million in 2022, then increased by 0.98% to $47.6 million in 2023, then increased by 8.59% to $51.7 million in 2024, then gained by 0.91% to $52.2 million in 2025, then fell by 2.64% to $50.8 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $50.8 million (Q1 2026), $52.2 million (Q4 2025), and $50.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 50.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.77 Mn |
| Dec 31, 2025 | 52.15 Mn |
| Sep 30, 2025 | 50.26 Mn |
| Jun 30, 2025 | 50.37 Mn |
| Mar 31, 2025 | 49.91 Mn |
| Dec 31, 2024 | 51.68 Mn |
| Sep 30, 2024 | 49.09 Mn |
| Jun 30, 2024 | 48.69 Mn |
| Mar 31, 2024 | 48.14 Mn |
| Dec 31, 2023 | 47.59 Mn |
| Sep 30, 2023 | 47.65 Mn |
| Jun 30, 2023 | 47.48 Mn |
| Mar 31, 2023 | 47.39 Mn |
| Dec 31, 2022 | 47.13 Mn |
| Sep 30, 2022 | 47.18 Mn |
| Jun 30, 2022 | 47.05 Mn |
| Mar 31, 2022 | 46.99 Mn |
| Dec 31, 2021 | 46.47 Mn |
| Sep 30, 2021 | 46.67 Mn |
| Jun 30, 2021 | 46.40 Mn |